低分子肝素钙序贯利伐沙班治疗急性肺栓塞的临床效果

Clinical Effect of Low Molecular Weight Heparin Calcium Sequential Rivaroxaban in the Treatment of Acute Pulmonary Embolism

目的:探讨低分子肝素钙序贯利伐沙班在急性肺栓塞患者中的应用价值。方法:将2021年7月—2023年7月辽宁电力中心医院收治的86例急性肺栓塞患者随机分为研究组(43例,采用低分子肝素钙序贯利伐沙班治疗)与对照组(43例,采用低分子肝素钙序贯华法林治疗)。比较两组治疗效果、凝血功能、血细胞水平、生命体征、不良反应发生情况。结果:与对照组相比,研究组治疗总有效率更高(P=0.049);治疗后,两组各凝血功能指标均优于治疗前,且研究组纤维蛋白原、D-二聚体水平低于对照组,凝血酶原时间、活化部分凝血活酶时间长于对照组(P<0.05);治疗后,两组血小板计数、血红蛋白、红细胞水平均高于治疗前,且研究组高于对照组(P<0.05);治疗后,两组动脉血氧分压升高,呼吸频率、心率降低,且研究组优于对照组(P<0.05);研究组不良反应发生率为9.30%,对照组为13.95%,无统计学差异(P>0.05)。结论:低分子肝素钙序贯利伐沙班治疗有助于控制急性肺栓塞患者的病情,改善凝血功能、血细胞水平,稳定生命体征,降低不良反应发生率。

Objective:To investigate the clinical effect of low molecular weight heparin calcium sequential rivaroxaban in the treatment of acute pulmonary embolism.Methods:A total of 86 patients with acute pulmonary embolism admitted to Liaoning Electric Power Central Hospital from July 2021 to July 2023 were randomly divided into a study group(43 cases,received low molecular weight heparin calcium sequential rivaroxaban treatment)and a control group(43 cases,received low molecular weight heparin calcium sequential warfarin treatment).The two groups were compared in terms of therapeutic effect,coagulation function,blood cell level,vital signs and adverse reactions.Results:Compared with the control group,the total response rate was higher in the study group(P=0.049);after treatment,the coagulation function indexes of the two groups were better than before treatment,and the levels of fibrinogen and D-dimer in the study group were lower than those in the control group,and the prothrombin time and activated partial thromboplastin time were longer than those in the control group(P<0.05);after treatment,the platelet count,hemoglobin and red blood cell levels in both groups were higher than before treatment,and the study group was higher than the control group(P<0.05);after treatment,the partial pressure of arterial blood oxygen increased,respiratory rate and heart rate decreased,and the study group was better than the control group(P<0.05);the adverse reactions rate was 9.30%in the study group and 13.95%in the control group,with no statistical difference(P>0.05).Conclusion:Low molecular weight heparin calcium sequential rivaroxaban therapy can help patients with acute pulmonary embolism to fully control the disease,improve coagulation function,blood cell level,stabilize vital signs,and reduce the incidence of adverse reactions.